Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP)

BACKGROUND: New regimens may provide better tolerability, convenience, and safety for nonoccupational human immunodeficiency virus (HIV) postexposure prophylaxis (PEP). For this reason, we evaluated the single-tablet regimen of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) for 28...

Descripción completa

Detalles Bibliográficos
Autores principales: Inciarte, Alexy, Ugarte, Ainoa, Martínez-Rebollar, María, Torres, Berta, Fernández, Emma, Berrocal, Leire, Laguno, Montserrat, De la Mora, Lorena, De Lazzari, Elisa, Callau, Pilar, Chivite, Iván, González-Cordón, Ana, Solbes, Estela, Rico, Verónica, Barrero, Laura, Blanco, José Luis, Martínez, Esteban, Ambrosioni, Juan, Mallolas, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394723/
https://www.ncbi.nlm.nih.gov/pubmed/37539061
http://dx.doi.org/10.1093/ofid/ofad374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394723/
https://www.ncbi.nlm.nih.gov/pubmed/37539061
http://dx.doi.org/10.1093/ofid/ofad374

Ejemplares similares